Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing ; volume:15 ; number:1 ; day:12 ; month:2 ; year:2015 ; pages:1-12 ; date:12.2015
BMC cancer ; 15, Heft 1 (12.2.2015), 1-12, 12.2015
- Creator
-
Cavelier, Lucia
- Contributor
-
Ameur, Adam
Häggqvist, Susana
Höijer, Ida
Cahill, Nicola
Olsson-Strömberg, Ulla
Hermanson, Monica
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1046-y
- URN
-
urn:nbn:de:1111-2016110614809
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cavelier, Lucia
- Ameur, Adam
- Häggqvist, Susana
- Höijer, Ida
- Cahill, Nicola
- Olsson-Strömberg, Ulla
- Hermanson, Monica
- SpringerLink (Online service)
Other Objects (12)
The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Analysis of transcripts and splice isoforms in red clover (Trifolium pratense L.) by single-molecule long-read sequencing
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
Decrypting the role of HSP90α and β isoforms in BCR-ABL1+ leukemia and Characterization of Small Molecule HSP90 Inhibitors and Degraders
The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia
The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Analysis of transcripts and splice isoforms in red clover (Trifolium pratense L.) by single-molecule long-read sequencing
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
Decrypting the role of HSP90α and β isoforms in BCR-ABL1+ leukemia and Characterization of Small Molecule HSP90 Inhibitors and Degraders
The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia
The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Analysis of transcripts and splice isoforms in red clover (Trifolium pratense L.) by single-molecule long-read sequencing
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
Decrypting the role of HSP90α and β isoforms in BCR-ABL1+ leukemia and Characterization of Small Molecule HSP90 Inhibitors and Degraders